Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/23/2025 | $8.00 | Underweight → Equal Weight | Wells Fargo |
4/17/2025 | $8.00 | Underweight | Wells Fargo |
2/6/2025 | $31.00 | Outperform | Wedbush |
12/6/2024 | $42.00 | Buy | H.C. Wainwright |
11/5/2024 | $48.00 | Buy | Rodman & Renshaw |
10/8/2024 | Overweight | Cantor Fitzgerald | |
10/8/2024 | $35.00 | Overweight | Morgan Stanley |
10/8/2024 | Buy | TD Cowen |
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that members of management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 3:20 p.m. ET. A live webcast of the presentation will be accessible through the Investor Relations section of Bicara's website under Events and Presentations. A replay of the webcast will be archived and available following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharma
Wells Fargo upgraded Bicara Therapeutics from Underweight to Equal Weight and set a new price target of $8.00
Wells Fargo initiated coverage of Bicara Therapeutics with a rating of Underweight and set a new price target of $8.00
Wedbush initiated coverage of Bicara Therapeutics with a rating of Outperform and set a new price target of $31.00
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
SCHEDULE 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)
144 - Bicara Therapeutics Inc. (0002023658) (Subject)
Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m. ET BOSTON, June 01, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented updated data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head an
BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with updated interim data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. The company will host a conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to present the fulsome dataset
SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
SC 13D - Bicara Therapeutics Inc. (0002023658) (Subject)
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.